Jubbonti (denosumab-bbdz) is an FDA-approved biosimilar designated as interchangeable with Prolia (denosumab). Both target the RANKL protein to stop bone breakdown, treat postmenopausal osteoporosis, and increase bone mass with identical clinical efficacy and safety.

Truxima (rituximab-abbs) is an FDA-approved biosimilar to Rituxan (rituximab). Both are targeted anti-CD20 monoclonal antibodies administered via intravenous infusion to treat rheumatoid arthritis, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia with matching clinical outcomes and safety.

Wezlana (ustekinumab-auub) is an FDA-approved biosimilar that is interchangeable with Stelara (ustekinumab). Both target IL-12 and IL-23 cytokines to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis with equal safety and effectiveness.

Inflectra (infliximab-dyyb) is an FDA-approved biosimilar to Remicade (infliximab). Both are intravenous TNF-blocker biologics designed to treat moderate-to-severe Crohn's disease and ulcerative colitis with identical clinical effectiveness and safety.

Biosimilars like Hyrimoz, Hadlima, and Yuflyma are highly similar, FDA-approved alternatives to Humira (adalimumab). They offer the exact same safety, clinical strength, and effectiveness as the original biologic, often at a significantly lower cost.

Cymbalta (duloxetine) is a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) that treats both mood disorders and chronic physical pain, whereas Wellbutrin (bupropion) is a Norepinephrine-Dopamine Reuptake Inhibitor (NDRI) known for boosting energy without causing weight gain or sexual dysfunction.